Hero image with Pittsburgh background pittplusme.org/study/1538

Pitt+Me A Study to Evaluate Risankizumab in Participants with Moderate to Severe Atopic Dermatitis


STUDY BASICS

Have you been diagnosed with moderate-to-severe atopic dermatitis (eczema) for at least the past 2 years? If so, you may be eligible to participate in a study of an investigational drug called risankizumab in subjects with atopic dermatitis. Involves 11 visits over up to 65 weeks. Compensation is provided.


IRB:
  33624/13 - A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis

Age Range
AGE:   18 and Up

Duration DURATION:  Up to 65 weeks
VISITS:  11 visits & 1 phone call

Location LOCATION: 
Falk Medical Building - Oakland
Compensation COMPENSATION: 
$78.00 per visit & travel reimbursement
Phone Number PHONE NUMBER:
1-866-438-8230
I'M INTERESTED
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   FacebookFacebook   TwitterTwitter   Linked-InLinked-In
Search Icon pittplusme.org/study/1538
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Laura Ferris

Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe facebook twitter

Pitt+Me

This website is maintained by the Clinical and Translational Science Institute.
© Copyright 2018, University of Pittsburgh. All rights reserved.